Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the latest version of Genedata Expressionist for Mass Spectrometry (MS) will be showcased at the “11th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry” organized by CASSS.
Developed in collaboration with leading mass spectrometry labs, the enterprise software platform automates and standardizes complex data analysis workflows in biopharmaceutical research and development — from raw data to final reports. Supporting instruments from all major vendors, Genedata Expressionist reduces data analysis times by factors of ten or more to accelerate the identification and quantification of critical quality attributes of biopharmaceuticals.
Vendor-agnostic Solution Solves Data Analysis Bottleneck
Today, characterization of biopharmaceuticals using mass spectrometry is a standard procedure within biopharmaceutical R&D. While automation of sample handling and mass spectrometry instrumentation enable high throughput applications, data analysis often remains a manual process. Genedata Expressionist for MS allows scientists to quickly and easily deliver on even the most complex and data-rich characterization projects within all parts of the R&D pipeline. The system covers the entire data analysis process, from raw data import over quality control and data refinement to statistical analysis and reporting.
The software features proprietary algorithms and reporting capabilities for processing samples in batches. Innovative and interactive multidimensional data visualization tools allow for reliable identification of false positive and false negative peptides. Genedata Expressionist for MS is regularly used in projects focusing on the identification of impurities, assessment of post-translational modifications (PTMs), and quality control of protein batches. It specifically supports the analysis of intact masses, protein sequence variants, N- and C-terminals, glycopeptides, released
glycans, and disulphide bonds.
"We have developed the latest version of Genedata Expressionist for MS together with leading experts from major biopharmaceutical organizations, and we are proud to say that the software helps our customers to implement efficient and standardized biopharmaceuticals characterization processes," said Dr. Othmar Pfannes, CEO of Genedata. "Combined with our continued commitment to developing vendor-agnostic solutions, this makes Expressionist for MS the platform of choice for all biopharmaceutical R&D organizations."
Genedata Expressionist for MS will be demonstrated at table #6 at the CASSS event
(Silverado Hotel, Napa, CA; September 09-12, 2014).
Technical Seminar, Wednesday, September 10, 12:30 – 13:30 pm
“Characterization of Biotherapeutics with Mass Spectrometry: Addressing the Data Analysis Bottleneck"
by Steve Pomerantz; Janssen
“Software for the Complete Characterization of Biopharmaceutical Molecules”
by Joe Shambaugh; Genedata Inc.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.